Identifying Cardiac Amyloid in Aortic Stenosis: ECV Quantification by CT in TAVR Patients

Paul R Scully, Kush P Patel, Bunny Saberwal, Ernst Klotz, João B Augusto, George D Thornton, Rebecca K Hughes, Charlotte Manisty, Guy Lloyd, James D Newton, Nikant Sabharwal, Andrew Kelion, Simon Kennon, Muhiddin Ozkor, Michael Mullen, Neil Hartman, João L Cavalcante, Leon J Menezes, Philip N Hawkins, Thomas A Treibel, James C Moon, Francesca Pugliese, Paul R Scully, Kush P Patel, Bunny Saberwal, Ernst Klotz, João B Augusto, George D Thornton, Rebecca K Hughes, Charlotte Manisty, Guy Lloyd, James D Newton, Nikant Sabharwal, Andrew Kelion, Simon Kennon, Muhiddin Ozkor, Michael Mullen, Neil Hartman, João L Cavalcante, Leon J Menezes, Philip N Hawkins, Thomas A Treibel, James C Moon, Francesca Pugliese

Abstract

Objectives: The purpose of this study was to validate computed tomography measured ECV (ECVCT) as part of routine evaluation for the detection of cardiac amyloid in patients with aortic stenosis (AS)-amyloid.

Background: AS-amyloid affects 1 in 7 elderly patients referred for transcatheter aortic valve replacement (TAVR). Bone scintigraphy with exclusion of a plasma cell dyscrasia can diagnose transthyretin-related cardiac amyloid noninvasively, for which novel treatments are emerging. Amyloid interstitial expansion increases the myocardial extracellular volume (ECV).

Methods: Patients with severe AS underwent bone scintigraphy (Perugini grade 0, negative; Perugini grades 1 to 3, increasingly positive) and routine TAVR evaluation CT imaging with ECVCT using 3- and 5-min post-contrast acquisitions. Twenty non-AS control patients also had ECVCT performed using the 5-min post-contrast acquisition.

Results: A total of 109 patients (43% male; mean age 86 ± 5 years) with severe AS and 20 control subjects were recruited. Sixteen (15%) had AS-amyloid on bone scintigraphy (grade 1, n = 5; grade 2, n = 11). ECVCT was 32 ± 3%, 34 ± 4%, and 43 ± 6% in Perugini grades 0, 1, and 2, respectively (p < 0.001 for trend) with control subjects lower than lone AS (28 ± 2%; p < 0.001). ECVCT accuracy for AS-amyloid detection versus lone AS was 0.87 (0.95 for 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid Perugini grade 2 only), outperforming conventional electrocardiogram and echocardiography parameters. One composite parameter, the voltage/mass ratio, had utility (similar AUC of 0.87 for any cardiac amyloid detection), although in one-third of patients, this could not be calculated due to bundle branch block or ventricular paced rhythm.

Conclusions: ECVCT during routine CT TAVR evaluation can reliably detect AS-amyloid, and the measured ECVCT tracks the degree of infiltration. Another measure of interstitial expansion, the voltage/mass ratio, also performed well.

Keywords: aortic stenosis; cardiac amyloidosis; computed tomography; extracellular volume.

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
ECVCT Protocol and Offline Analysis Integrated Into TAVR Planning Cardiac CT Text in red represents additional image acquisition/reconstruction in scanning protocol for the extracellular volume quantification by computed tomography (ECVCT). Text in blue represents steps in off-line analysis. ASM = axial shuttle mode; CT = computed tomography; CTCA = computed tomography coronary angiography; ECV = extracellular volume; ROI = region of interest.
Figure 2
Figure 2
Automated ECVCT Heart Model Output With Corresponding 3-h Planar DPD Image ECVCT map superimposed on the CTCA images (A to D) and corresponding 3-h planar DPD image (E). The endocardial and epicardial contours can be edited in the short-axis (A), 4-chamber (B), and 2-chamber (D) views to produce an ECVCT American Heart Association 17-segment polar map (C). This is a patient with aortic stenosis (AS) amyloid (Perugini grade 2 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid [DPD] scintigraphy) with total myocardial ECVCT is globally elevated at 47%. Abbreviations as in Figure 1.
Figure 3
Figure 3
Box and Whisker Plot Showing the Variation in ECVCT Between DPD Perugini Grades p 

Central Illustration

ECV CT for the Detection…

Central Illustration

ECV CT for the Detection of Cardiac Amyloidosis in Aortic Stenosis Extracellular volume…

Central Illustration
ECVCT for the Detection of Cardiac Amyloidosis in Aortic Stenosis Extracellular volume (ECV) quantification by computed tomography (ECVCT) polar maps (top), 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) planar (middle), and axial single-photon emission computed tomography images (bottom) from control (far left) through lone aortic stenosis (AS), DPD Perugini grade 1, and DPD Perugini grade 2 (far right).

Figure 4

Receiver-Operating Characteristic Curve for the…

Figure 4

Receiver-Operating Characteristic Curve for the Detection of Any Cardiac Amyloid (DPD Perugini Grade…

Figure 4
Receiver-Operating Characteristic Curve for the Detection of Any Cardiac Amyloid (DPD Perugini Grade 1 or 2) Using ECVCT With a 3-Min Post-Contrast Acquisition, PWd, and MCF The voltage/mass ratio was not included because this approach would have excluded nearly one-third of patients (32 in total) due to bundle branch block or ventricular paced rhythm. AUC = area under the curve; CI = confidence interval; MCF = myocardial contraction fraction; PWd = posterior wall diameter; other abbreviations as in Figure 1.

Figure 5

Proposed ECV CT Screening Algorithm…

Figure 5

Proposed ECV CT Screening Algorithm for Incorporation Into Routine Clinical Workflow The algorithm…

Figure 5
Proposed ECVCT Screening Algorithm for Incorporation Into Routine Clinical Workflow The algorithm can be adjusted to an ECVCT threshold of ≥29% for the detection of all grade 1 DPD patients. TAVR = transcatheter aortic valve replacement; other abbreviations as in Figures 1 and 2.
All figures (7)
Central Illustration
Central Illustration
ECVCT for the Detection of Cardiac Amyloidosis in Aortic Stenosis Extracellular volume (ECV) quantification by computed tomography (ECVCT) polar maps (top), 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) planar (middle), and axial single-photon emission computed tomography images (bottom) from control (far left) through lone aortic stenosis (AS), DPD Perugini grade 1, and DPD Perugini grade 2 (far right).
Figure 4
Figure 4
Receiver-Operating Characteristic Curve for the Detection of Any Cardiac Amyloid (DPD Perugini Grade 1 or 2) Using ECVCT With a 3-Min Post-Contrast Acquisition, PWd, and MCF The voltage/mass ratio was not included because this approach would have excluded nearly one-third of patients (32 in total) due to bundle branch block or ventricular paced rhythm. AUC = area under the curve; CI = confidence interval; MCF = myocardial contraction fraction; PWd = posterior wall diameter; other abbreviations as in Figure 1.
Figure 5
Figure 5
Proposed ECVCT Screening Algorithm for Incorporation Into Routine Clinical Workflow The algorithm can be adjusted to an ECVCT threshold of ≥29% for the detection of all grade 1 DPD patients. TAVR = transcatheter aortic valve replacement; other abbreviations as in Figures 1 and 2.

References

    1. Lung B. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:1231–1243.
    1. Thaden J.J., Nkomo V.T., Enriquez-Sarano M. The global burden of aortic stenosis. Prog Cardiovasc Dis. 2014;56:565–571.
    1. Lindroos M., Kupari M., Heikkilä J., Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993;21:1220–1225.
    1. Turina J., Hess O., Sepulcri F., Krayenbuehl H.P. Spontaneous course of aortic valve disease. Eur Heart J. 1987;8:471–483.
    1. Leon M.B., Smith C.R., Mack M.J. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–1620.
    1. Mack M.J., Leon M.B., Thourani V.H., Makkar R., Kodali S.K., Russo M. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695–1705.
    1. Tanskanen M., Peuralinna T., Polvikoski T. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau : a population-based autopsy study. Ann Med. 2008;40:232–239.
    1. Scully P.R., Treibel T.A., Fontana M. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol. 2018;71:463–464.
    1. Castaño A., Narotsky D.L., Hamid N. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–2887.
    1. Maurer M.S., Schwartz J.H., Gundapaneni B. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–1016.
    1. Solomon S.D., Adams D., Kristen A. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO Study. Circulation. 2019;139:431–443.
    1. Dasgupta N.R., Benson M. Improved survival of patients with transthyretin amyloid cardiomyopathy with inotersen (TTR specific antisense oligonucleotide) J Am Coll Cardiol. 2019;73:811.
    1. Gillmore J.D., Maurer M.S., Falk R.H. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–2412.
    1. Scully P.R., Bastarrika G., Moon J.C., Treibel T.A. Myocardial extracellular volume quantification by cardiovascular magnetic resonance and computed tomography. Curr Cardiol Rep. 2018;20
    1. Sado D.M., Flett A.S., Banypersad S.M. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart. 2012;98:1436–1441.
    1. Banypersad S.M., Sado D.M., Flett A.S. Quantification of myocardial extracellular volume fraction in systemic al amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6:34–39.
    1. Bandula S., White S.K., Flett A.S. Measurement of myocardial extracellular volume fraction by using equilibrium contrast-enhanced CT: validation against histologic findings. Radiology. 2013;269:396–403.
    1. Treibel T.A., Bandula S., Fontana M. Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. J Cardiovasc Comput Tomogr. 2015;9:585–592.
    1. Scully P.R., Patel K.P., Treibel T.A. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41:2759–2767.
    1. Sokolow M., Lyon T.P. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161–186.
    1. Hancock E.W., Deal B.J., Mirvis D.M., Okin P., Kligfield P., Gettes L.S. AHA/ACCF/HRS Recommendations for the standardization and interpretation of the electrocardiogram: Part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009;53:992–1002.
    1. Baumgartner H., Hung J., Bermejo J. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2017;30:372–392.
    1. Wharton G., Steeds R., Allen J. A minimum dataset for a standard adult transthoracic echocardiogram: a guideline protocol from the British Society of Echocardiography. Echo Res Pract. 2015;2:G9–G24.
    1. Nagueh S.F., Smiseth O.A., Appleton C.P. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.
    1. Lang R.M., Badano L.P., Mor-Avi V. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–271.
    1. Devereux R.B., Alonso D.R., Lutas E.M. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458.
    1. Rubin J., Steidley D.E., Carlsson M., Ong M.L., Maurer M.S. Myocardial contraction fraction by M-mode echocardiography is superior to ejection fraction in predicting mortality in transthyretin amyloidosis. J Card Fail. 2018;24:504–511.
    1. Perugini E., Guidalotti P.L., Salvi F. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076–1084.
    1. Scully P.R., Morris E., Patel K.P. DPD Quantification in Cardiac Amyloidosis: a Novel Imaging Biomarker. J Am Coll Cardiol Img. 2020;13:1353–1363.
    1. Nacif M.S., Kawel N., Lee J.J. Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT. Radiology. 2012;264:876–883.
    1. Nacif M.S., Liu Y., Yao J. 3D left ventricular extracellular volume fraction by low-radiation dose cardiac CT: assessment of interstitial myocardial fibrosis. J Cardiovasc Comput Tomogr. 2013;7:51–57.
    1. Trattner S., Halliburton S., Thompson C.M. Cardiac-specific conversion factors to estimate radiation effective dose from dose-length product in computed tomography. J Am Coll Cardiol Img. 2018;11:64–74.
    1. Cavalcante J.L., Rijal S., Abdelkarim I. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson. 2017;19
    1. Treibel T.A., Fontana M., Gilbertson J.A. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016;9
    1. González-López E., Gallego-Delgado M., Guzzo-Merello G. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585–2594.
    1. Damy T., Costes B., Hagège A.A. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37:1826–1834.
    1. Coles L.S., Young R.D. Supercentenarians and transthyretin amyloidosis: the next frontier of human life extension. Prev Med. 2012;54:S9–S11.
    1. Auffret V., Webb J.G., Eltchaninoff H. Clinical impact of baseline right bundle branch block in patients undergoing transcatheter aortic valve replacement. J Am Coll Cardiol Intv. 2017;10:1564–1574.
    1. Watanabe Y., Kozuma K., Hioki H. Pre-existing right bundle branch block increases risk for death after transcatheter aortic valve replacement with a balloon-expandable valve. J Am Coll Cardiol Intv. 2016;9:2210–2216.
    1. Martinez-Naharro A., Abdel-Gadir A., Treibel T.A. CMR-verified regression of cardiac AL amyloid after chemotherapy. J Am Coll Cardiol Img. 2018;11:152–154.
    1. Kurita Y., Kitagawa K., Kurobe Y. Estimation of myocardial extracellular volume fraction with cardiac CT in subjects without clinical coronary artery disease: a feasibility study. J Cardiovasc Comput Tomogr. 2016;10:237–241.
    1. Treibel T.A., López B., González A. Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. Eur Heart J. 2018;39:699–709.

Source: PubMed

3
Subscribe